Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme

AstraZeneca1,387 enrolled

Overview

Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms changes over 6 months in schizophrenia in patients treated with Seroquel; additionally disease severity and treatment compliance are followed

Study Type

OBSERVATIONAL

Enrollment

1,387

Conditions

Schizophrenia

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * To assess at baseline and after treatment administration the severity of the illness in patients with schizophrenia, using the scores obtained after the application of the CGI scale * To assess the changes in symptoms of patients treated with Seroquel for 24 weeks, using BPRS (Brief Psychiatry Rating Scale) as measuring tool Exclusion Criteria: * All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of its excipients will not be included in this study.

Outcomes

Primary Outcomes

Brief Psychiatric Rating Scale - BPRS

Time frame: Monthly at every clinic visit- 7 times

Secondary Outcomes

Clinical Global Impression Severity of Illness

Time frame: Monthly/ at every clinic visit-7 times

CGI-S Clinical Global Impression Improvement CGI -I

Time frame: Monthly/ at every clinic visit except first visit- 6 times

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.